ID   DH-My6
AC   CVCL_WV40
DR   Wikidata; Q93526724
RX   PubMed=30323893;
CC   Population: Japanese.
CC   Doubling time: 20 hours (PubMed=30323893).
CC   Sequence variation: Gene fusion; HGNC; HGNC:1001; BCL6 + HGNC; HGNC:5477; IGH; Name(s)=IGH-BCL6 (PubMed=30323893).
CC   Sequence variation: Gene fusion; HGNC; HGNC:5477; IGH + HGNC; HGNC:7553; MYC; Name(s)=MYC-IGH (PubMed=30323893).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): PubMed=30323893
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 8
ST   D16S539: 12,13
ST   D21S11: 30
ST   D5S818: 10,12
ST   D7S820: 10,12
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C125904; High grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements
DI   ORDO; Orphanet_480541; High grade B-cell lymphoma with MYC and/or BCL2 and/or BCL6 rearrangement
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   54Y
CA   Cancer cell line
DT   Created: 05-07-19; Last updated: 19-12-24; Version: 9
//
RX   PubMed=30323893; DOI=10.18632/oncotarget.26060; PMCID=PMC6173362;
RA   Kikuchi H., Higuchi T., Hashida Y., Taniguchi A., Kamioka M.,
RA   Taguchi T., Yokoyama A., Murakami I., Fujieda M., Daibata M.;
RT   "Generation and characteristics of a novel 'double-hit' high grade
RT   B-cell lymphoma cell line DH-My6 with MYC/IGH and BCL6/IGH gene
RT   arrangements and potential molecular targeted therapies.";
RL   Oncotarget 9:33482-33499(2018).
//